Tamoxifen is widely used in the treatment of estrogen receptor-positive breast cancer and has been found to inhibit the myofibroblastic differentiation of pancreatic stellate cells (PSCs) and cell invasion into the tumor microenvironment [28], but it has not been used in the treatment of pancreatic cancer. This evidence concerns the gene ESR1 and familial pancreatic carcinoma.